Pet Biopharmaceuticals - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511246108

Publication Date:

November 7, 2024

Pages:

111

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Pet Biopharmaceuticals was estimated to be worth US$ 14270 million in 2023 and is forecast to a readjusted size of US$ 19590 million by 2030 with a CAGR of 4.7% during the forecast period 2024-2030
Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from 拢2.6bn in 2015 to 拢4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China's Pet Healthy Consumption of JD shows that in 2023, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China's pet medical market is about 楼67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 47%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pet Biopharmaceuticals, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pet Biopharmaceuticals by region & country, by Type, and by Application.
The Pet Biopharmaceuticals market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pet Biopharmaceuticals.
麻豆原创 Segmentation
By Company
Zoetis
Boehringer Ingelheim
Merck
Elanco
Virbac
Dechra Veterinary Products
Ceva
Vetoquinol
Ouro Fino Saude
Norbrook
Jindun
Chopperlvya Animal Health
CAHIC
Segment by Type:
Antiparasitic
Biological Products
Antibacterial
Others
Segment by Application
Prevention
Treatment
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pet Biopharmaceuticals manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Pet Biopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Pet Biopharmaceuticals in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Pet Biopharmaceuticals Product Introduction
1.2 Global Pet Biopharmaceuticals 麻豆原创 Size Forecast
1.3 Pet Biopharmaceuticals 麻豆原创 Trends & Drivers
1.3.1 Pet Biopharmaceuticals Industry Trends
1.3.2 Pet Biopharmaceuticals 麻豆原创 Drivers & Opportunity
1.3.3 Pet Biopharmaceuticals 麻豆原创 Challenges
1.3.4 Pet Biopharmaceuticals 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Pet Biopharmaceuticals Players Revenue Ranking (2023)
2.2 Global Pet Biopharmaceuticals Revenue by Company (2019-2024)
2.3 Key Companies Pet Biopharmaceuticals Manufacturing Base Distribution and Headquarters
2.4 Key Companies Pet Biopharmaceuticals Product Offered
2.5 Key Companies Time to Begin Mass Production of Pet Biopharmaceuticals
2.6 Pet Biopharmaceuticals 麻豆原创 Competitive Analysis
2.6.1 Pet Biopharmaceuticals 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Pet Biopharmaceuticals Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pet Biopharmaceuticals as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Antiparasitic
3.1.2 Biological Products
3.1.3 Antibacterial
3.1.4 Others
3.2 Global Pet Biopharmaceuticals Sales Value by Type
3.2.1 Global Pet Biopharmaceuticals Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Pet Biopharmaceuticals Sales Value, by Type (2019-2030)
3.2.3 Global Pet Biopharmaceuticals Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Prevention
4.1.2 Treatment
4.2 Global Pet Biopharmaceuticals Sales Value by Application
4.2.1 Global Pet Biopharmaceuticals Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Pet Biopharmaceuticals Sales Value, by Application (2019-2030)
4.2.3 Global Pet Biopharmaceuticals Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Pet Biopharmaceuticals Sales Value by Region
5.1.1 Global Pet Biopharmaceuticals Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Pet Biopharmaceuticals Sales Value by Region (2019-2024)
5.1.3 Global Pet Biopharmaceuticals Sales Value by Region (2025-2030)
5.1.4 Global Pet Biopharmaceuticals Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Pet Biopharmaceuticals Sales Value, 2019-2030
5.2.2 North America Pet Biopharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Pet Biopharmaceuticals Sales Value, 2019-2030
5.3.2 Europe Pet Biopharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Pet Biopharmaceuticals Sales Value, 2019-2030
5.4.2 Asia Pacific Pet Biopharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Pet Biopharmaceuticals Sales Value, 2019-2030
5.5.2 South America Pet Biopharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Pet Biopharmaceuticals Sales Value, 2019-2030
5.6.2 Middle East & Africa Pet Biopharmaceuticals Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Pet Biopharmaceuticals Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Pet Biopharmaceuticals Sales Value
6.3 United States
6.3.1 United States Pet Biopharmaceuticals Sales Value, 2019-2030
6.3.2 United States Pet Biopharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Pet Biopharmaceuticals Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Pet Biopharmaceuticals Sales Value, 2019-2030
6.4.2 Europe Pet Biopharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Pet Biopharmaceuticals Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Pet Biopharmaceuticals Sales Value, 2019-2030
6.5.2 China Pet Biopharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.5.3 China Pet Biopharmaceuticals Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Pet Biopharmaceuticals Sales Value, 2019-2030
6.6.2 Japan Pet Biopharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Pet Biopharmaceuticals Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Pet Biopharmaceuticals Sales Value, 2019-2030
6.7.2 South Korea Pet Biopharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Pet Biopharmaceuticals Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Pet Biopharmaceuticals Sales Value, 2019-2030
6.8.2 Southeast Asia Pet Biopharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Pet Biopharmaceuticals Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Pet Biopharmaceuticals Sales Value, 2019-2030
6.9.2 India Pet Biopharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.9.3 India Pet Biopharmaceuticals Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Zoetis
7.1.1 Zoetis Profile
7.1.2 Zoetis Main Business
7.1.3 Zoetis Pet Biopharmaceuticals Products, Services and Solutions
7.1.4 Zoetis Pet Biopharmaceuticals Revenue (US$ Million) & (2019-2024)
7.1.5 Zoetis Recent Developments
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Profile
7.2.2 Boehringer Ingelheim Main Business
7.2.3 Boehringer Ingelheim Pet Biopharmaceuticals Products, Services and Solutions
7.2.4 Boehringer Ingelheim Pet Biopharmaceuticals Revenue (US$ Million) & (2019-2024)
7.2.5 Boehringer Ingelheim Recent Developments
7.3 Merck
7.3.1 Merck Profile
7.3.2 Merck Main Business
7.3.3 Merck Pet Biopharmaceuticals Products, Services and Solutions
7.3.4 Merck Pet Biopharmaceuticals Revenue (US$ Million) & (2019-2024)
7.3.5 Elanco Recent Developments
7.4 Elanco
7.4.1 Elanco Profile
7.4.2 Elanco Main Business
7.4.3 Elanco Pet Biopharmaceuticals Products, Services and Solutions
7.4.4 Elanco Pet Biopharmaceuticals Revenue (US$ Million) & (2019-2024)
7.4.5 Elanco Recent Developments
7.5 Virbac
7.5.1 Virbac Profile
7.5.2 Virbac Main Business
7.5.3 Virbac Pet Biopharmaceuticals Products, Services and Solutions
7.5.4 Virbac Pet Biopharmaceuticals Revenue (US$ Million) & (2019-2024)
7.5.5 Virbac Recent Developments
7.6 Dechra Veterinary Products
7.6.1 Dechra Veterinary Products Profile
7.6.2 Dechra Veterinary Products Main Business
7.6.3 Dechra Veterinary Products Pet Biopharmaceuticals Products, Services and Solutions
7.6.4 Dechra Veterinary Products Pet Biopharmaceuticals Revenue (US$ Million) & (2019-2024)
7.6.5 Dechra Veterinary Products Recent Developments
7.7 Ceva
7.7.1 Ceva Profile
7.7.2 Ceva Main Business
7.7.3 Ceva Pet Biopharmaceuticals Products, Services and Solutions
7.7.4 Ceva Pet Biopharmaceuticals Revenue (US$ Million) & (2019-2024)
7.7.5 Ceva Recent Developments
7.8 Vetoquinol
7.8.1 Vetoquinol Profile
7.8.2 Vetoquinol Main Business
7.8.3 Vetoquinol Pet Biopharmaceuticals Products, Services and Solutions
7.8.4 Vetoquinol Pet Biopharmaceuticals Revenue (US$ Million) & (2019-2024)
7.8.5 Vetoquinol Recent Developments
7.9 Ouro Fino Saude
7.9.1 Ouro Fino Saude Profile
7.9.2 Ouro Fino Saude Main Business
7.9.3 Ouro Fino Saude Pet Biopharmaceuticals Products, Services and Solutions
7.9.4 Ouro Fino Saude Pet Biopharmaceuticals Revenue (US$ Million) & (2019-2024)
7.9.5 Ouro Fino Saude Recent Developments
7.10 Norbrook
7.10.1 Norbrook Profile
7.10.2 Norbrook Main Business
7.10.3 Norbrook Pet Biopharmaceuticals Products, Services and Solutions
7.10.4 Norbrook Pet Biopharmaceuticals Revenue (US$ Million) & (2019-2024)
7.10.5 Norbrook Recent Developments
7.11 Jindun
7.11.1 Jindun Profile
7.11.2 Jindun Main Business
7.11.3 Jindun Pet Biopharmaceuticals Products, Services and Solutions
7.11.4 Jindun Pet Biopharmaceuticals Revenue (US$ Million) & (2019-2024)
7.11.5 Jindun Recent Developments
7.12 Chopperlvya Animal Health
7.12.1 Chopperlvya Animal Health Profile
7.12.2 Chopperlvya Animal Health Main Business
7.12.3 Chopperlvya Animal Health Pet Biopharmaceuticals Products, Services and Solutions
7.12.4 Chopperlvya Animal Health Pet Biopharmaceuticals Revenue (US$ Million) & (2019-2024)
7.12.5 Chopperlvya Animal Health Recent Developments
7.13 CAHIC
7.13.1 CAHIC Profile
7.13.2 CAHIC Main Business
7.13.3 CAHIC Pet Biopharmaceuticals Products, Services and Solutions
7.13.4 CAHIC Pet Biopharmaceuticals Revenue (US$ Million) & (2019-2024)
7.13.5 CAHIC Recent Developments
8 Industry Chain Analysis
8.1 Pet Biopharmaceuticals Industrial Chain
8.2 Pet Biopharmaceuticals Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Pet Biopharmaceuticals Sales Model
8.5.2 Sales Channel
8.5.3 Pet Biopharmaceuticals Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Zoetis
Boehringer Ingelheim
Merck
Elanco
Virbac
Dechra Veterinary Products
Ceva
Vetoquinol
Ouro Fino Saude
Norbrook
Jindun
Chopperlvya Animal Health
CAHIC

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.